[go: up one dir, main page]

FI954514L - 3-O-deasyloitua monofosforyylilipidiä A sisältävä rokotekoostumus - Google Patents

3-O-deasyloitua monofosforyylilipidiä A sisältävä rokotekoostumus Download PDF

Info

Publication number
FI954514L
FI954514L FI954514A FI954514A FI954514L FI 954514 L FI954514 L FI 954514L FI 954514 A FI954514 A FI 954514A FI 954514 A FI954514 A FI 954514A FI 954514 L FI954514 L FI 954514L
Authority
FI
Finland
Prior art keywords
composition containing
vaccine composition
monophosphoryl lipid
deacylated monophosphoryl
deacylated
Prior art date
Application number
FI954514A
Other languages
English (en)
Swedish (sv)
Other versions
FI954514A0 (fi
FI110844B (fi
Inventor
Pierre Hauser
Pierre Voet
Moncef Slaoui
Nathalie Marie- Garcon-Johnson
Pierre Desmons
Original Assignee
Smithkline Beecham Biolog
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26302633&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI954514(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB939306029A external-priority patent/GB9306029D0/en
Priority claimed from GB9403417A external-priority patent/GB9403417D0/en
Application filed by Smithkline Beecham Biolog filed Critical Smithkline Beecham Biolog
Publication of FI954514A0 publication Critical patent/FI954514A0/fi
Publication of FI954514L publication Critical patent/FI954514L/fi
Application granted granted Critical
Publication of FI110844B publication Critical patent/FI110844B/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FI954514A 1993-03-23 1995-09-22 Menetelmä 3-O-deasyloidun monofosforyylilipidin A valmistamiseksi FI110844B (fi)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB9306029 1993-03-23
GB939306029A GB9306029D0 (en) 1993-03-23 1993-03-23 Vaccine compositions
GB9403417 1994-02-23
GB9403417A GB9403417D0 (en) 1994-02-23 1994-02-23 Vaccine compositions
EP9400818 1994-03-14
PCT/EP1994/000818 WO1994021292A1 (en) 1993-03-23 1994-03-14 Vaccine compositions containing 3-o deacylated monophosphoryl lipid a

Publications (3)

Publication Number Publication Date
FI954514A0 FI954514A0 (fi) 1995-09-22
FI954514L true FI954514L (fi) 1995-09-22
FI110844B FI110844B (fi) 2003-04-15

Family

ID=26302633

Family Applications (1)

Application Number Title Priority Date Filing Date
FI954514A FI110844B (fi) 1993-03-23 1995-09-22 Menetelmä 3-O-deasyloidun monofosforyylilipidin A valmistamiseksi

Country Status (28)

Country Link
US (1) US5776468A (fi)
EP (3) EP0812593B8 (fi)
JP (2) JP4028593B2 (fi)
KR (1) KR100310510B1 (fi)
CN (1) CN1087176C (fi)
AP (1) AP515A (fi)
AT (2) ATE204762T1 (fi)
AU (1) AU685443B2 (fi)
BR (1) BR9405957A (fi)
CZ (1) CZ289476B6 (fi)
DE (2) DE69405551T3 (fi)
DK (2) DK0812593T4 (fi)
DZ (1) DZ1763A1 (fi)
ES (2) ES2162139T5 (fi)
FI (1) FI110844B (fi)
GR (1) GR3025483T3 (fi)
HK (1) HK1045935A1 (fi)
HU (1) HU219056B (fi)
IL (1) IL109056A (fi)
MA (1) MA23143A1 (fi)
NO (2) NO322578B1 (fi)
NZ (1) NZ263538A (fi)
PL (1) PL178578B1 (fi)
PT (1) PT812593E (fi)
SA (1) SA94140762B1 (fi)
SG (1) SG48309A1 (fi)
SK (1) SK117395A3 (fi)
WO (1) WO1994021292A1 (fi)

Families Citing this family (444)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9105992D0 (en) * 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
US6620414B2 (en) * 1992-03-27 2003-09-16 Smithkline Beecham Biologicals (S.A.) Hepatitis vaccines containing 3-0-deacylated monophoshoryl lipid A
RU2160120C2 (ru) * 1992-05-23 2000-12-10 Смитклайн Бичам Байолоджикалс С.А. Комбинированная вакцина на основе поверхностного антигена вируса гепатита в, способ ее получения и способ предупреждения инфекции гепатита в у человека
EP0705109B2 (en) * 1993-05-25 2004-01-02 American Cyanamid Company Adjuvants for vaccines against respiratory syncytial virus
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US6488934B1 (en) 1995-02-25 2002-12-03 Smithkline Beecham Biologicals S.A. Hepatitis B vaccine
GB9503863D0 (en) * 1995-02-25 1995-04-19 Smithkline Beecham Biolog Vaccine compositions
UA56132C2 (uk) * 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US6696065B1 (en) * 1995-05-04 2004-02-24 Aventis Pastuer Limited Acellular pertussis vaccines and methods of preparation thereof
PT909323E (pt) 1996-01-04 2007-06-04 Novartis Vaccines & Diagnostic ''bacterioferritina de helicobacter pilori''
US20060024301A1 (en) * 1997-02-25 2006-02-02 Corixa Corporation Prostate-specific polypeptides and fusion polypeptides thereof
US7517952B1 (en) * 1997-02-25 2009-04-14 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US20060269532A1 (en) * 1997-02-25 2006-11-30 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US20030185830A1 (en) * 1997-02-25 2003-10-02 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6491919B2 (en) 1997-04-01 2002-12-10 Corixa Corporation Aqueous immunologic adjuvant compostions of monophosphoryl lipid A
ATE278419T1 (de) * 1997-04-01 2004-10-15 Corixa Corp Wässerige immunologische adjuvantzusammensetzungen aus monophosphoryllipid a
GB9706957D0 (en) * 1997-04-05 1997-05-21 Smithkline Beecham Plc Formulation
US6368604B1 (en) 1997-09-26 2002-04-09 University Of Maryland Biotechnology Institute Non-pyrogenic derivatives of lipid A
GB9724531D0 (en) 1997-11-19 1998-01-21 Smithkline Biolog Novel compounds
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US6761888B1 (en) * 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
US7179892B2 (en) * 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
US6923964B1 (en) 1997-12-02 2005-08-02 Neuralab Limited Active immunization of AScr for prion disorders
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US7588766B1 (en) 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
DE19803453A1 (de) * 1998-01-30 1999-08-12 Boehringer Ingelheim Int Vakzine
GB9808866D0 (en) 1998-04-24 1998-06-24 Smithkline Beecham Biolog Novel compounds
US20030147882A1 (en) * 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
AU4193399A (en) * 1998-05-22 1999-12-13 Smithkline Beecham Biologicals (Sa) Correlative protection using ospa antibody titers
DK1096954T3 (da) * 1998-07-14 2005-01-31 Wyeth Corp Adjuvans- og vaccinesammensætninger indeholdende monophosphoryllipid A
US6306404B1 (en) 1998-07-14 2001-10-23 American Cyanamid Company Adjuvant and vaccine compositions containing monophosphoryl lipid A
US20040213806A1 (en) * 1998-08-28 2004-10-28 Smithkline Beecham Biologicals, S.A. Salmonella typhi vaccine compositions
US6692752B1 (en) 1999-09-08 2004-02-17 Smithkline Beecham Biologicals S.A. Methods of treating human females susceptible to HSV infection
GB9819898D0 (en) * 1998-09-11 1998-11-04 Smithkline Beecham Plc New vaccine and method of use
GB9820525D0 (en) * 1998-09-21 1998-11-11 Allergy Therapeutics Ltd Formulation
GB9822714D0 (en) 1998-10-16 1998-12-09 Smithkline Beecham Sa Vaccines
CN100406060C (zh) * 1998-10-16 2008-07-30 史密丝克莱恩比彻姆生物有限公司 一种佐剂组合物
EP2374889A3 (en) 1998-12-08 2012-02-22 GlaxoSmithKline Biologicals SA Novel compounds
AU3164600A (en) 1999-03-12 2000-10-04 Smithkline Beecham Biologicals (Sa) Novel compounds
DE122009000054I1 (de) 1999-03-19 2009-12-31 Glaxosmithkline Biolog Sa Impfstoff gegen bakterielle antigene
GB9909077D0 (en) * 1999-04-20 1999-06-16 Smithkline Beecham Biolog Novel compositions
CN1227030C (zh) 1999-04-19 2005-11-16 史密丝克莱恩比彻姆生物有限公司 包含皂甙和免疫刺激寡核苷酸的佐剂组合物
US6558670B1 (en) 1999-04-19 2003-05-06 Smithkline Beechman Biologicals S.A. Vaccine adjuvants
BR0010539A (pt) * 1999-05-13 2002-02-19 American Cyanamid Co Composição antigênica, e, método para incrementar a capacidade de uma composição antigênica
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
UA81216C2 (en) * 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
US6635261B2 (en) 1999-07-13 2003-10-21 Wyeth Holdings Corporation Adjuvant and vaccine compositions containing monophosphoryl lipid A
GB9921147D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
GB9921146D0 (en) 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
GB9923176D0 (en) * 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
EP1227837B1 (en) 1999-10-22 2008-05-21 Aventis Pasteur Limited Method of inducing and/or enhancing an immune response to tumor antigens
EP1104767A1 (en) 1999-11-30 2001-06-06 Stichting Dienst Landbouwkundig Onderzoek Mono- and disaccharide derivatives containing both fatty acid ester and sulfate ester groups
GB0000891D0 (en) * 2000-01-14 2000-03-08 Allergy Therapeutics Ltd Formulation
ATE513913T1 (de) 2000-05-10 2011-07-15 Sanofi Pasteur Ltd Durch mage minigene kodierte immunogene polypeptide und ihre verwendungen
US6821519B2 (en) * 2000-06-29 2004-11-23 Corixa Corporation Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
GB0022742D0 (en) 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
US20020155997A1 (en) * 2000-10-06 2002-10-24 Kurt Zimmermann Kyberdrug as autovaccines with immune-regulating effects
PT1326638E (pt) * 2000-10-18 2008-02-06 Glaxosmithkline Biolog Sa Vacinas contra cancros
NZ594877A (en) 2000-10-27 2012-07-27 Novartis Vaccines & Diagnostic Nucleic acids and proteins from streptococcus groups A & B
US7048931B1 (en) * 2000-11-09 2006-05-23 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
WO2002038177A2 (en) * 2000-11-10 2002-05-16 Wyeth Holdings Corporation Adjuvant combination formulations
PE20020574A1 (es) * 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
WO2002046477A2 (en) 2000-12-07 2002-06-13 Chiron Corporation Endogenous retroviruses up-regulated in prostate cancer
ATE503493T1 (de) 2001-02-23 2011-04-15 Glaxosmithkline Biolog Sa Influenza vakzinzusammensetzungen zur intradermaler verabreichung
US20030031684A1 (en) 2001-03-30 2003-02-13 Corixa Corporation Methods for the production of 3-O-deactivated-4'-monophosphoryl lipid a (3D-MLA)
GB0109297D0 (en) 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
US20100221284A1 (en) 2001-05-30 2010-09-02 Saech-Sisches Serumwerk Dresden Novel vaccine composition
TWI228420B (en) 2001-05-30 2005-03-01 Smithkline Beecham Pharma Gmbh Novel vaccine composition
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
US8481043B2 (en) 2001-06-22 2013-07-09 Cpex Pharmaceuticals, Inc. Nasal immunization
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
US7361352B2 (en) 2001-08-15 2008-04-22 Acambis, Inc. Influenza immunogen and vaccine
AR045702A1 (es) 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
WO2003070909A2 (en) 2002-02-20 2003-08-28 Chiron Corporation Microparticles with adsorbed polypeptide-containing molecules
US7351413B2 (en) 2002-02-21 2008-04-01 Lorantis, Limited Stabilized HBc chimer particles as immunogens for chronic hepatitis
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
ATE545651T1 (de) 2002-06-13 2012-03-15 Novartis Vaccines & Diagnostic Vektoren zur expression von hml-2-polypeptiden
EP2351579B1 (en) 2002-10-11 2016-09-21 Novartis Vaccines and Diagnostics S.r.l. Polypeptide vaccines for broad protection against hypervirulent meningococcal lineages
CA2502268A1 (en) 2002-10-23 2004-05-06 Glaxosmithkline Biologicals S.A. Methods for vaccinating against malaria
US7858098B2 (en) 2002-12-20 2010-12-28 Glaxosmithkline Biologicals, S.A. Vaccine
CN101926988B (zh) 2003-01-30 2014-06-04 诺华疫苗和诊断有限公司 抗多种脑膜炎球菌血清组的可注射性疫苗
PE20050627A1 (es) 2003-05-30 2005-08-10 Wyeth Corp Anticuerpos humanizados que reconocen el peptido beta amiloideo
ES2328697T5 (es) 2003-06-02 2017-07-25 Novartis Vaccines And Diagnostics, Inc. Composiciones inmunogénicas basadas en micropartículas que comprenden toxoide adsorbido y un antígeno que contiene un polisacárido
GB0321615D0 (en) 2003-09-15 2003-10-15 Glaxo Group Ltd Improvements in vaccination
AU2004277342B2 (en) 2003-10-02 2010-12-16 Glaxosmithkline Biologicals S.A. Pertussis antigens and use thereof in vaccination
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
JP4738339B2 (ja) 2003-10-02 2011-08-03 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル 複数の髄膜炎菌血清群についての液体ワクチン
WO2005107797A1 (en) 2004-03-09 2005-11-17 Chiron Corporation Influenza virus vaccines
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
NZ550533A (en) 2004-04-30 2010-02-26 Novartis Vaccines & Diagnostic Meningococcal conjugate vaccination comprising N. meningitidis and diphtheria toxin
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
GB0410866D0 (en) 2004-05-14 2004-06-16 Chiron Srl Haemophilius influenzae
EP2848692B1 (en) 2004-05-21 2017-08-16 Novartis Vaccines and Diagnostics, Inc. Alphavirus vectors for influenza virus vaccines
JP2008500984A (ja) 2004-05-28 2008-01-17 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ヴィロソームとサポニンアジュバントを含むワクチン組成物
US7758866B2 (en) 2004-06-16 2010-07-20 Glaxosmithkline Biologicals, S.A. Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52
US20090317420A1 (en) 2004-07-29 2009-12-24 Chiron Corporation Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
GB0417494D0 (en) 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine
AU2005287505A1 (en) 2004-09-22 2006-03-30 Biosynexus Incorporated Staphylococcal immunogenic compositions
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
WO2006062637A2 (en) * 2004-11-03 2006-06-15 Novartis Vaccines And Diagnostics Inc. Influenza vaccination
US7625560B2 (en) * 2004-12-15 2009-12-01 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
PE20061329A1 (es) 2004-12-15 2006-12-08 Neuralab Ltd Anticuerpos ab humanizados para mejorar la cognicion
CN101107007B (zh) 2005-01-27 2011-08-17 奥克兰儿童医院及研究中心 对脑膜炎奈瑟球菌所致疾病具有广谱保护作用的gna1870囊泡疫苗
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
JP2008530195A (ja) * 2005-02-16 2008-08-07 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド リン酸アルミニウムおよび３ｄ−ｍｐｌを含むアジュバント組成物
GB0503337D0 (en) 2005-02-17 2005-03-23 Glaxosmithkline Biolog Sa Compositions
SG164344A1 (en) 2005-02-18 2010-09-29 Novartis Vaccines & Diagnostics Srl Immunogens from uropathogenic escherichia coli
DK2351772T3 (en) 2005-02-18 2016-09-05 Glaxosmithkline Biologicals Sa Proteins and nucleic acids from meningitis / sepsis-associated Escherichia coli
GB0504436D0 (en) 2005-03-03 2005-04-06 Glaxosmithkline Biolog Sa Vaccine
TW200700078A (en) 2005-03-23 2007-01-01 Glaxosmithkline Biolog Sa Novel use
SG175456A1 (en) 2005-04-18 2011-11-28 Novartis Vaccines & Diagnostic Expressing hepatitis b virus surface antigen for vaccine preparation
KR20120089475A (ko) 2005-04-29 2012-08-10 인펙셔스 디지즈 리서치 인스티튜트 (아이디알아이) 결핵균 감염을 예방 또는 치료하기 위한 신규한 방법
GB0513421D0 (en) 2005-06-30 2005-08-03 Glaxosmithkline Biolog Sa Vaccines
US20110223197A1 (en) 2005-10-18 2011-09-15 Novartis Vaccines And Diagnostics Inc. Mucosal and Systemic Immunization with Alphavirus Replicon Particles
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
US8697087B2 (en) 2005-11-04 2014-04-15 Novartis Ag Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
AU2006310163B2 (en) 2005-11-04 2011-09-15 Seqirus UK Limited Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant
AU2006310337B9 (en) 2005-11-04 2013-11-28 Novartis Ag Adjuvanted influenza vaccines including cytokine-inducing agents
PL1945252T3 (pl) 2005-11-04 2013-11-29 Seqirus Uk Ltd Szczepionki zawierające oczyszczone antygeny powierzchniowe otrzymane z wirusów grypy hodowanych w hodowli komórkowej i skwalen jako adiuwant
NZ568210A (en) * 2005-11-04 2012-12-21 Novartis Vaccines & Diagnostic Emulsions with free aqueous-phase surfactant as adjuvants for split influenza vaccines
GB0522765D0 (en) 2005-11-08 2005-12-14 Chiron Srl Combination vaccine manufacture
EP2360175B1 (en) 2005-11-22 2014-07-16 Novartis Vaccines and Diagnostics, Inc. Norovirus and Sapovirus virus-like particles (VLPs)
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
PT1973564T (pt) 2005-12-22 2017-01-24 Glaxosmithkline Biologicals Sa Vacina compreendendo conjugados polissacarídicos capsulares de streptococcus pneumoniae
US8617565B2 (en) 2006-01-17 2013-12-31 Arne Forsgren et al. Surface exposed Haemophilus influenzae protein (protein E; pE)
WO2007085969A2 (en) 2006-01-27 2007-08-02 Novartis Vaccines And Diagnostics Gmbh & Co Kg Influenza vaccines containing hemagglutinin and matrix proteins
US8173657B2 (en) 2006-03-23 2012-05-08 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
US8063063B2 (en) 2006-03-23 2011-11-22 Novartis Ag Immunopotentiating compounds
CN101448523A (zh) 2006-03-24 2009-06-03 诺华疫苗和诊断有限两合公司 无需冷藏储存流感疫苗
BRPI0710210A2 (pt) 2006-03-30 2011-05-24 Glaxomithkline Biolog S A composição imunogênica, vacina, métodos para preparar a vacina, e para prevenir ou tratar infecção estafilocócica, uso da composição imunogênica, e, processo para conjugar oligassacarìdeo ou polissacarìdeo capsular
US9839685B2 (en) 2006-04-13 2017-12-12 The Regents Of The University Of Michigan Methods of inducing human immunodeficiency virus-specific immune responses in a host comprising nasally administering compositions comprising a naonemulsion and recombinant GP120 immunogen
US10138279B2 (en) 2006-04-13 2018-11-27 Regents Of The University Of Michigan Compositions and methods for Bacillus anthracis vaccination
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US20100015168A1 (en) 2006-06-09 2010-01-21 Novartis Ag Immunogenic compositions for streptococcus agalactiae
PL2422810T3 (pl) 2006-07-17 2015-03-31 Glaxosmithkline Biologicals Sa Szczepionka przeciw grypie
WO2008009652A2 (en) 2006-07-18 2008-01-24 Glaxosmithkline Biologicals S.A. Vaccines for malaria
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
WO2008012538A2 (en) 2006-07-25 2008-01-31 The Secretary Of State For Defence Live vaccine strains of francisella
US20100166788A1 (en) 2006-08-16 2010-07-01 Novartis Vaccines And Diagnostics Immunogens from uropathogenic escherichia coli
JP5954921B2 (ja) 2006-09-11 2016-07-20 ノバルティス アーゲー 卵を使用しないインフルエンザウイルスワクチンの作製
EP2484375B1 (en) 2006-09-26 2018-05-23 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
PL2601970T3 (pl) 2006-09-29 2017-07-31 Takeda Vaccines, Inc. Preparaty szczepionki przeciw norowirusowi
PL2086582T3 (pl) 2006-10-12 2013-04-30 Glaxosmithkline Biologicals Sa Kompozycja zawierająca adiuwant w postaci emulsji typu olej w wodzie
WO2008043774A1 (en) 2006-10-12 2008-04-17 Glaxosmithkline Biologicals S.A. Vaccine comprising an oil in water emulsion adjuvant
WO2008068631A2 (en) 2006-12-06 2008-06-12 Novartis Ag Vaccines including antigen from four strains of influenza virus
CN101675068A (zh) 2007-03-02 2010-03-17 葛兰素史密丝克莱恩生物有限公司 新的方法和组合物
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
US9452209B2 (en) 2007-04-20 2016-09-27 Glaxosmithkline Biologicals Sa Influenza vaccine
AU2008267208B2 (en) 2007-06-26 2012-01-19 Glaxosmithkline Biologicals S.A. Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates
EA201070066A1 (ru) 2007-06-27 2010-06-30 Новартис Аг Вакцины против гриппа с низким содержанием добавок
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
SI2182983T1 (sl) 2007-07-27 2014-09-30 Janssen Alzheimer Immunotherapy Zdravljenje amiloidogenih bolezni s humaniziranimi protitelesi proti abeta
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
HUE025149T2 (hu) 2007-08-02 2016-01-28 Biondvax Pharmaceuticals Ltd Multimer multiepitóp influenza vakcinák
CN102027003A (zh) 2007-08-03 2011-04-20 哈佛大学校长及研究员协会 衣原体抗原
MX2010001752A (es) 2007-08-13 2010-03-10 Glaxosmithkline Biolog Sa Vacunas.
EP2197485B1 (en) 2007-09-12 2015-11-11 GlaxoSmithKline Biologicals SA Gas57 mutant antigens and gas57 antibodies
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
US8637053B2 (en) 2007-12-03 2014-01-28 President And Fellows Of Harvard College Chlamydia antigens
ES2664753T3 (es) 2007-12-07 2018-04-23 Glaxosmithkline Biologicals Sa Composiciones de inducción de respuestas inmunes
WO2009117035A1 (en) 2007-12-19 2009-09-24 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Soluble forms of hendra and nipah virus f glycoprotein and uses thereof
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
PL2235046T3 (pl) 2007-12-21 2012-12-31 Novartis Ag Zmutowane formy streptolizyny O
CN101952321B (zh) 2007-12-24 2016-05-11 葛兰素史密斯克莱生物公司 重组rsv抗原
WO2009104097A2 (en) 2008-02-21 2009-08-27 Novartis Ag Meningococcal fhbp polypeptides
US8506966B2 (en) 2008-02-22 2013-08-13 Novartis Ag Adjuvanted influenza vaccines for pediatric use
AU2009223613B2 (en) 2008-03-10 2014-09-25 Children's Hospital & Research Center At Oakland Chimeric factor H binding proteins (fHBP) containing a heterologous B domain and methods of use
AU2009227674C1 (en) 2008-03-18 2015-01-29 Seqirus UK Limited Improvements in preparation of influenza virus vaccine antigens
BRPI0910963A2 (pt) 2008-04-16 2016-01-05 Glaxosmithkline Biolog Sa composição imunogênica, método para tratar ou prevenir doença pneumocócica, e , uso de uma composição imunogênica
US9415006B2 (en) 2008-05-23 2016-08-16 The Regents Of The University Of Michigan Immunogenic compositions comprising nanoemulsion and hepatitis B virus immunogen and methods of using the same
CA2731194A1 (en) * 2008-07-18 2010-01-21 Id Biomedical Corporation Of Quebec Chimeric respiratory syncytial virus polypeptide antigens
GB0815872D0 (en) 2008-09-01 2008-10-08 Pasteur Institut Novel method and compositions
WO2010036945A2 (en) 2008-09-26 2010-04-01 The Regents Of The University Of Michigan Nanoemulsion therapeutic compositions and methods of using the same
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
US9974844B2 (en) 2008-11-17 2018-05-22 The Regents Of The University Of Michigan Cancer vaccine compositions and methods of using the same
AU2009323682A1 (en) 2008-12-03 2010-06-10 Protea Vaccine Technologies Ltd. Glutamyl tRNA synthetase (GtS) fragments
PE20110891A1 (es) 2008-12-09 2011-12-23 Pfizer Vaccines Llc Vacuna de peptido ch3 de ige
WO2010079081A1 (en) 2009-01-07 2010-07-15 Glaxosmithkline Biologicals S.A. Methods for recovering a virus or a viral antigen produced by cell culture
AU2010204139A1 (en) 2009-01-12 2011-08-11 Novartis Ag Cna_B domain antigens in vaccines against gram positive bacteria
GB0901411D0 (en) 2009-01-29 2009-03-11 Secr Defence Treatment
GB0901423D0 (en) 2009-01-29 2009-03-11 Secr Defence Treatment
JP5843615B2 (ja) 2009-02-06 2016-01-13 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 密度勾配超遠心分離によるウイルスまたはウイルス抗原の精製
US9278126B2 (en) 2009-02-10 2016-03-08 Seqirus UK Limited Influenza vaccines with reduced amounts of squalene
MX338898B (es) 2009-02-17 2016-05-03 Glaxosmithkline Biolog Sa Vacuna contra el virus del dengue inactivado con un adyuvante libre de aluminio.
CA2754533C (en) 2009-03-05 2019-07-09 Jenny Colleen Mccloskey Treatment of infection
ES2733084T3 (es) 2009-03-06 2019-11-27 Glaxosmithkline Biologicals Sa Antígenos de Chlamydia
GB0906234D0 (en) 2009-04-14 2009-05-20 Secr Defence Vaccine
SG175092A1 (en) 2009-04-14 2011-11-28 Novartis Ag Compositions for immunising against staphylococcus aerus
RU2536248C2 (ru) 2009-04-30 2014-12-20 Коули Фармасьютикал Груп, Инк. Пневмококковая вакцина и ее применения
RU2732574C2 (ru) 2009-06-05 2020-09-21 Инфекшес Дизиз Рисерч Инститьют Синтетические глюкопиранозиллипидные адъюванты
GB0910046D0 (en) * 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
EP2944320A1 (en) 2009-06-15 2015-11-18 National University of Singapore Influenza vaccine, composition, and methods of use
ES2566646T3 (es) 2009-06-16 2016-04-14 The Regents Of The University Of Michigan Vacunas en nanoemulsión
UA111141C2 (uk) 2009-06-24 2016-04-11 Глаксосмітклайн Байолоджікалз С.А. Рекомбінантні антигени рсв
AU2010264686A1 (en) 2009-06-24 2012-01-19 Glaxosmithkline Biologicals S.A. Vaccine
WO2011004263A2 (en) 2009-07-07 2011-01-13 Novartis Ag Conserved escherichia coli immunogens
ES2918381T3 (es) 2009-07-15 2022-07-15 Glaxosmithkline Biologicals Sa Composiciones de proteína F de VRS y métodos para producir las mismas
WO2011007257A1 (en) 2009-07-16 2011-01-20 Novartis Ag Detoxified escherichia coli immunogens
KR20130127547A (ko) 2009-07-30 2013-11-22 화이자 백신스 엘엘씨 항원성 타우 펩타이드 및 이의 용도
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
EP2470204B1 (en) 2009-08-27 2015-12-16 GlaxoSmithKline Biologicals SA Hybrid polypeptides including meningococcal fhbp sequences
MX2012002639A (es) 2009-09-03 2012-03-14 Pfizer Vaccines Llc Vacuna de pcsk9.
EP2475385A1 (en) 2009-09-10 2012-07-18 Novartis AG Combination vaccines against respiratory tract diseases
ES2538474T3 (es) 2009-09-25 2015-06-22 Glaxosmithkline Biologicals S.A. Ensayo de inmunodifusión para el virus de la gripe
GB0917003D0 (en) 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Purification of bacterial vesicles
GB0917002D0 (en) 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Improved shigella blebs
AU2010302344A1 (en) 2009-09-30 2012-04-26 Novartis Ag Expression of meningococcal fhbp polypeptides
MX373250B (es) 2009-09-30 2020-05-04 Glaxosmithkline Biologicals S A Star Conjugación de polisacáridos capsulares de tipo 5 y de tipo 8 de staphylococcus aureus.
GB0918392D0 (en) 2009-10-20 2009-12-02 Novartis Ag Diagnostic and therapeutic methods
CN102917730A (zh) 2009-10-27 2013-02-06 诺华有限公司 修饰的脑膜炎球菌fHBP多肽
GB0919117D0 (en) 2009-10-30 2009-12-16 Glaxosmithkline Biolog Sa Process
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
WO2011067758A2 (en) 2009-12-02 2011-06-09 Protea Vaccine Technologies Ltd. Immunogenic fragments and multimers from streptococcus pneumoniae proteins
DE102009056871A1 (de) * 2009-12-03 2011-06-22 Novartis AG, 4056 Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben
AU2010334428B2 (en) 2009-12-22 2015-05-21 Celldex Therapeutics, Inc. Vaccine compositions
WO2011080595A2 (en) 2009-12-30 2011-07-07 Novartis Ag Polysaccharide immunogens conjugated to e. coli carrier proteins
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
GB201003924D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Immunogenic composition
GB201003920D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Method of treatment
EP2552480A1 (en) 2010-03-26 2013-02-06 GlaxoSmithKline Biologicals S.A. Hiv vaccine
ES2661569T3 (es) 2010-03-30 2018-04-02 Children's Hospital & Research Center At Oakland Proteínas de unión al factor H (fHbp) con propiedades alteradas y métodos de uso de las mismas
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
WO2011127316A1 (en) 2010-04-07 2011-10-13 Novartis Ag Method for generating a parvovirus b19 virus-like particle
EP2558069A1 (en) 2010-04-13 2013-02-20 Novartis AG Benzonapthyridine compositions and uses thereof
JP6200805B2 (ja) 2010-05-03 2017-09-20 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 新規な方法
EP2575988A1 (en) 2010-05-28 2013-04-10 Tetris Online, Inc. Interactive hybrid asynchronous computer game infrastructure
GB201009273D0 (en) 2010-06-03 2010-07-21 Glaxosmithkline Biolog Sa Novel vaccine
EP2575868A1 (en) 2010-06-07 2013-04-10 Pfizer Vaccines LLC Ige ch3 peptide vaccine
WO2011154863A1 (en) 2010-06-07 2011-12-15 Pfizer Inc. Her-2 peptides and vaccines
GB201009861D0 (en) 2010-06-11 2010-07-21 Novartis Ag OMV vaccines
US8658603B2 (en) 2010-06-16 2014-02-25 The Regents Of The University Of Michigan Compositions and methods for inducing an immune response
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
CN103154242B (zh) 2010-07-06 2015-09-30 诺华股份有限公司 诺如病毒衍生的免疫原性组合物和方法
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
CA2812893A1 (en) 2010-09-27 2012-04-05 Glaxosmithkline Biologicals S.A. Vaccine
US9168292B2 (en) 2010-09-27 2015-10-27 Crucell Holland B.V. Heterologous prime boost vaccination regimen against malaria
CA2813522C (en) 2010-10-15 2022-06-21 Guy Jean Marie Fernand Pierre Baudoux Cytomegalovirus gb polypeptide antigens and uses thereof
GB201017519D0 (en) 2010-10-15 2010-12-01 Novartis Vaccines Inst For Global Health S R L Vaccines
FR2966044B1 (fr) * 2010-10-18 2012-11-02 Sanofi Pasteur Procede de conditionnement d'un vaccin contenant un adjuvant d'aluminium
WO2012072769A1 (en) 2010-12-01 2012-06-07 Novartis Ag Pneumococcal rrgb epitopes and clade combinations
US9550811B2 (en) 2010-12-02 2017-01-24 Bionor Immuno As Peptide scaffold design
KR20190022897A (ko) 2010-12-14 2019-03-06 글락소스미스클라인 바이오로지칼즈 에스.에이. 미코박테리움 항원성 조성물
US20130315959A1 (en) 2010-12-24 2013-11-28 Novartis Ag Compounds
GB201022007D0 (en) 2010-12-24 2011-02-02 Imp Innovations Ltd DNA-sensor
EA034031B1 (ru) 2011-01-06 2019-12-20 Бионор Иммуно Ас Димерный пептид для индуцирования иммунного ответа против hiv и его применение
LT2667892T (lt) 2011-01-26 2019-05-10 Glaxosmithkline Biologicals Sa Rsv imunizacijos režimas
CN103517713A (zh) 2011-02-22 2014-01-15 彼昂德瓦克斯医药有限公司 在改善的季节性和大流行性流感疫苗中的多聚体多表位多肽
WO2012131504A1 (en) 2011-03-02 2012-10-04 Pfizer Inc. Pcsk9 vaccine
GB201106357D0 (en) 2011-04-14 2011-06-01 Pessi Antonello Composition and uses thereof
MX350795B (es) 2011-04-08 2017-09-19 Inmune Design Corp Composiciones inmunogenicas y metodos para utilizar las composiciones para inducir respuestas inmunes humorales y celulares.
TW201302779A (zh) 2011-04-13 2013-01-16 Glaxosmithkline Biolog Sa 融合蛋白質及組合疫苗
AU2012255971A1 (en) 2011-05-13 2013-05-02 Novartis Ag Pre-fusion RSV F antigens
CN103533953A (zh) 2011-05-17 2014-01-22 葛兰素史密丝克莱恩生物有限公司 针对肺炎链球菌的疫苗
WO2013006569A2 (en) 2011-07-01 2013-01-10 The Regents Of The University Of California Herpes virus vaccine and methods of use
US11896636B2 (en) 2011-07-06 2024-02-13 Glaxosmithkline Biologicals Sa Immunogenic combination compositions and uses thereof
CA2841047A1 (en) 2011-07-06 2013-01-10 Novartis Ag Immunogenic compositions and uses thereof
WO2013009564A1 (en) 2011-07-08 2013-01-17 Novartis Ag Tyrosine ligation process
MX356586B (es) 2011-07-11 2018-06-05 Takeda Vaccines Inc Formulaciones parenterales de vacunas contra los norovirus.
WO2013016460A1 (en) 2011-07-25 2013-01-31 Novartis Ag Compositions and methods for assessing functional immunogenicity of parvovirus vaccines
GB201114923D0 (en) 2011-08-30 2011-10-12 Novartis Ag Immunogenic proteins and compositions
CA2847204A1 (en) 2011-09-01 2013-03-07 Novartis Ag Adjuvanted formulations of staphylococcus aureus antigens
US9358284B2 (en) 2011-09-14 2016-06-07 Glaxosmithkline Biologicals Sa Methods for making saccharide-protein glycoconjugates
SI2758432T1 (sl) 2011-09-16 2019-07-31 Ucb Biopharma Sprl Nevtralizirajoča protitelesa proti glavnim eksotoksinom TCDA in TCDB iz clostridium difficile
GB201116248D0 (en) 2011-09-20 2011-11-02 Glaxosmithkline Biolog Sa Liposome production using isopropanol
MX354924B (es) 2011-11-07 2018-03-22 Novartis Ag Molecula portadora que comprende un antigeno spr0096 y un spr2021.
EP2780034A1 (en) 2011-11-14 2014-09-24 Crucell Holland B.V. Heterologous prime-boost immunization using measles virus-based vaccines
WO2013108272A2 (en) 2012-01-20 2013-07-25 International Centre For Genetic Engineering And Biotechnology Blood stage malaria vaccine
EP2822586A1 (en) 2012-03-07 2015-01-14 Novartis AG Adjuvanted formulations of streptococcus pneumoniae antigens
US20150030630A1 (en) 2012-03-07 2015-01-29 Novartis Ag Adjuvanted formulations of rabies virus immunogens
MX372965B (es) 2012-03-08 2020-04-01 Glaxosmithkline Biologicals Sa Formulaciones adyuvadas de vacunas de difteria, tetanos y tos ferina (dtp) de refuerzo.
CN104159603A (zh) 2012-03-08 2014-11-19 诺华股份有限公司 带有tlr4激动剂的联合疫苗
JP2015514696A (ja) 2012-03-18 2015-05-21 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ヒト・パピローマウイルスに対するワクチン接種方法
EP3492095A1 (en) 2012-04-01 2019-06-05 Technion Research & Development Foundation Limited Extracellular matrix metalloproteinase inducer (emmprin) peptides and binding antibodies
EP2659907A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
EP2659908A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
EP2659906A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
KR102125658B1 (ko) 2012-05-04 2020-06-22 화이자 인코포레이티드 전립선 관련된 항원 및 백신 기재 면역치료 요법
DK2850431T3 (en) 2012-05-16 2018-07-16 Immune Design Corp Vaccines against HSV-2
WO2013174832A1 (en) 2012-05-22 2013-11-28 Novartis Ag Meningococcus serogroup x conjugate
EP2666785A1 (en) 2012-05-23 2013-11-27 Affiris AG Complement component C5a-based vaccine
BR112014030466A2 (pt) 2012-06-06 2017-09-12 Bionor Immuno As peptídeos derivados de proteínas virais para uso como imunógenos e reagentes de dosagem
CN104853770A (zh) 2012-07-06 2015-08-19 诺华股份有限公司 免疫原性组合物及其应用
AU2013301312A1 (en) 2012-08-06 2015-03-19 Glaxosmithkline Biologicals S.A. Method for eliciting in infants an immune response against RSV and B. pertussis
US20140037680A1 (en) 2012-08-06 2014-02-06 Glaxosmithkline Biologicals, S.A. Novel method
EP2703483A1 (en) 2012-08-29 2014-03-05 Affiris AG PCSK9 peptide vaccine
EP2892553A1 (en) 2012-09-06 2015-07-15 Novartis AG Combination vaccines with serogroup b meningococcus and d/t/p
EP4056198A3 (en) 2012-09-18 2022-12-07 GlaxoSmithKline Biologicals SA Outer membrane vesicles
CA2885625A1 (en) 2012-10-02 2014-04-10 Glaxosmithkline Biologicals S.A. Nonlinear saccharide conjugates
AR092897A1 (es) 2012-10-03 2015-05-06 Novartis Ag Composiciones inmunogenicas
SG11201502599TA (en) 2012-10-12 2015-05-28 Glaxosmithkline Biolog Sa Non-cross-linked acellular pertussis antigens for use in combination vaccines
AU2013351182C1 (en) 2012-11-30 2018-11-08 Glaxosmithkline Biologicals Sa Pseudomonas antigens and antigen combinations
LT3513806T (lt) 2012-12-05 2023-04-11 Glaxosmithkline Biologicals Sa Imunogeninė kompozicija
WO2014160463A1 (en) 2013-03-13 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Prefusion rsv f proteins and their use
EP2968521A2 (en) 2013-03-15 2016-01-20 GlaxoSmithKline Biologicals S.A. Vaccine
EA032326B1 (ru) 2013-04-18 2019-05-31 Иммьюн Дизайн Корп. Монотерапия gla для применения в лечении рака
US20210145963A9 (en) 2013-05-15 2021-05-20 The Governors Of The University Of Alberta E1e2 hcv vaccines and methods of use
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
GB201310008D0 (en) 2013-06-05 2013-07-17 Glaxosmithkline Biolog Sa Immunogenic composition for use in therapy
KR20160040290A (ko) 2013-08-05 2016-04-12 글락소스미스클라인 바이오로지칼즈 에스.에이. 조합 면역원성 조성물
WO2015028546A1 (en) 2013-08-30 2015-03-05 Glaxosmithkline Biologicals S.A. Large scale production of viruses in cell culture
JP6306700B2 (ja) 2013-11-01 2018-04-04 ユニバーシティ オブ オスロＵｎｉｖｅｒｓｉｔｙ ｏｆ Ｏｓｌｏ アルブミン改変体及びその使用
EP2870974A1 (en) 2013-11-08 2015-05-13 Novartis AG Salmonella conjugate vaccines
WO2015071763A2 (en) 2013-11-15 2015-05-21 Oslo Universitetssykehus Hf Ctl peptide epitopes and antigen-specific t cells, methods for their discovery, and uses thereof
WO2015092710A1 (en) 2013-12-19 2015-06-25 Glaxosmithkline Biologicals, S.A. Contralateral co-administration of vaccines
EP3607966A1 (en) 2014-01-21 2020-02-12 Pfizer Inc Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
EP3104877B1 (en) 2014-02-11 2020-01-22 The USA, as represented by The Secretary, Department of Health and Human Services Pcsk9 vaccine and methods of using the same
TW201620927A (zh) 2014-02-24 2016-06-16 葛蘭素史密斯克藍生物品公司 Ｕｓｐａ２蛋白質構築體及其用途
AU2014388299A1 (en) * 2014-03-25 2016-10-20 The Government Of The United States Of America As Represented By The Secretary Of The Army Methods for enhancing the immunostimulation potency of aluminum salt-adsorbed vaccines
HUE047808T2 (hu) 2014-03-26 2020-05-28 Glaxosmithkline Biologicals Sa Mutáns Staphylococcus antigének
BR112016028816A8 (pt) 2014-06-13 2021-07-20 Glaxosmithkline Biologicals Sa combinação imunogênica, método para obter uma resposta imunológica específica, uso de uma combinação imunogênica, e, regime de vacinação para prevenção, redução ou tratamento de infecção por vírus sincicial respiratório
PL3160500T3 (pl) 2014-06-25 2020-02-28 Glaxosmithkline Biologicals S.A. Immunogenna kompozycja clostridium difficile
US10759836B2 (en) 2014-07-18 2020-09-01 University Of Washington Cancer vaccine compositions and methods of use thereof
AR101256A1 (es) 2014-07-21 2016-12-07 Sanofi Pasteur Composición vacunal que comprende ipv y ciclodextrinas
CN106715464B (zh) 2014-07-23 2021-03-16 奥克兰儿童医院及研究中心 因子h结合蛋白变体及其使用方法
EP3204039B1 (en) 2014-10-10 2022-06-08 The Regents Of The University Of Michigan Nanoemulsion compositions for preventing, suppressing or eliminating allergic and inflammatory disease
MA40920A (fr) 2014-11-07 2017-09-12 Takeda Vaccines Inc Vaccins de la main, du pied et de la bouche, et procédés de fabrication et d'utilisation de ceux-ci
AR102548A1 (es) 2014-11-07 2017-03-08 Takeda Vaccines Inc Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y uso
MX387007B (es) 2014-12-10 2025-03-19 Glaxosmithkline Biologicals Sa Una composición inmunogénica para usarse en el tratamiento o prevención de la infección por staphylococcus aureus.
FI3244917T3 (fi) 2015-01-15 2023-05-25 Pfizer Immunogeenisiä koostumuksia pneumokokkirokotteissa käytettäväksi
EP3268034A4 (en) 2015-03-05 2018-11-14 Northwestern University Non-neuroinvasive viruses and uses thereof
WO2016154010A1 (en) 2015-03-20 2016-09-29 Makidon Paul Immunogenic compositions for use in vaccination against bordetella
US10576131B2 (en) 2015-06-03 2020-03-03 Affiris Ag IL-23-p19 vaccines
JP2018524323A (ja) 2015-06-26 2018-08-30 セキラス ユーケー リミテッド 抗原がマッチしたインフルエンザワクチン
CN107849119A (zh) 2015-07-07 2018-03-27 阿费里斯股份公司 用于治疗和预防IgE介导的疾病的疫苗
KR102225282B1 (ko) 2015-07-21 2021-03-10 화이자 인코포레이티드 접합된 캡슐형 사카라이드 항원을 포함하는 면역원성 조성물, 그를 포함하는 키트 및 그의 용도
HK1248531A1 (zh) 2015-08-25 2018-10-19 巴比塔‧阿格拉沃尔 免疫调节组合物及其使用方法
CN117229414A (zh) 2015-10-08 2023-12-15 艾伯塔大学理事会 丙型肝炎病毒e1/e2异二聚体及其生产方法
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
GB201518668D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Immunogenic Comosition
WO2017085586A1 (en) 2015-11-20 2017-05-26 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
WO2017109698A1 (en) 2015-12-22 2017-06-29 Glaxosmithkline Biologicals Sa Immunogenic formulation
EP4659813A2 (en) 2016-03-14 2025-12-10 Universitetet I Oslo Engineered immunoglobulins with altered fcrn binding
WO2017158421A1 (en) 2016-03-14 2017-09-21 University Of Oslo Anti-viral engineered immunoglobulins
WO2017201390A1 (en) 2016-05-19 2017-11-23 The Regents Of The University Of Michigan Novel adjuvant compositions
GB201610599D0 (en) 2016-06-17 2016-08-03 Glaxosmithkline Biologicals Sa Immunogenic Composition
US11780924B2 (en) 2016-06-21 2023-10-10 University Of Oslo HLA binding vaccine moieties and uses thereof
US11498956B2 (en) 2016-08-23 2022-11-15 Glaxosmithkline Biologicals Sa Fusion peptides with antigens linked to short fragments of invariant chain(CD74)
GB201614799D0 (en) 2016-09-01 2016-10-19 Glaxosmithkline Biologicals Sa Compositions
WO2018060288A1 (en) 2016-09-29 2018-04-05 Glaxosmithkline Biologicals S.A. Compositions and methods of treatment of persistent hpv infection
GB201616904D0 (en) 2016-10-05 2016-11-16 Glaxosmithkline Biologicals Sa Vaccine
WO2018096396A1 (en) 2016-11-22 2018-05-31 University Of Oslo Albumin variants and uses thereof
CA3045952A1 (en) 2016-12-07 2018-06-14 Glaxosmithkline Biologicals Sa Novel process
GB201620968D0 (en) 2016-12-09 2017-01-25 Glaxosmithkline Biologicals Sa Adenovirus polynucleotides and polypeptides
US11084850B2 (en) 2016-12-16 2021-08-10 The Pirbright Institute Recombinant prefusion RSV F proteins and uses thereof
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
SI3570879T1 (sl) 2017-01-20 2022-06-30 Pfizer Inc. Imunogenska kompozicija za uporabo v pnevmokoknih cepivih
WO2018178265A1 (en) 2017-03-31 2018-10-04 Glaxosmithkline Intellectual Property Development Limited Immunogenic composition, use and method of treatment
WO2018178264A1 (en) 2017-03-31 2018-10-04 Glaxosmithkline Intellectual Property Development Limited Immunogenic composition, use and method of treatment
WO2018193063A2 (en) 2017-04-19 2018-10-25 Institute For Research In Biomedicine Novel malaria vaccines and antibodies binding to plasmodium sporozoites
US20210187098A1 (en) 2017-04-28 2021-06-24 Glaxosmithkline Biologicals Sa Vaccination
GB201707700D0 (en) 2017-05-12 2017-06-28 Glaxosmithkline Biologicals Sa Dried composition
IE87414B1 (en) 2017-05-30 2023-07-19 Glaxosmithkline Biologicals Sa Novel methods for manufacturing an adjuvant
CN110996994A (zh) 2017-08-14 2020-04-10 葛兰素史密丝克莱恩生物有限公司 加强免疫应答的方法
US12268736B2 (en) 2017-09-07 2025-04-08 University Of Oslo Vaccine molecules
EP3678699A1 (en) 2017-09-07 2020-07-15 University Of Oslo Vaccine molecules
AU2018330165B2 (en) 2017-09-08 2025-07-17 Access To Advanced Health Institute Liposomal formulations comprising saponin and methods of use
CN111556757A (zh) 2017-10-31 2020-08-18 西方溶瘤细胞有限公司 用于全身递送的平台溶瘤载体
CA3081578A1 (en) 2017-11-03 2019-05-09 Takeda Vaccines, Inc. Zika vaccines and immunogenic compositions, and methods of using the same
GB201721069D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B Immunisation regimen and compositions
GB201721068D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B immunisation regimen and compositions
GB201721582D0 (en) 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa S aureus antigens and immunogenic compositions
GB201721576D0 (en) 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa Hla antigens and glycoconjugates thereof
MX2020013553A (es) 2018-06-12 2021-02-26 Glaxosmithkline Biologicals Sa Polinucleotidos y polipeptidos de adenovirus.
EP3581201A1 (en) 2018-06-15 2019-12-18 GlaxoSmithKline Biologicals S.A. Escherichia coli o157:h7 proteins and uses thereof
CN110680909B (zh) * 2018-07-04 2024-09-20 辽宁成大生物股份有限公司 一种速释b型流感嗜血杆菌结合疫苗可溶性微针贴及其制备方法
BR112020027090A2 (pt) 2018-07-31 2021-03-30 Glaxosmithkline Biologicals S.A. Método de purificação de antígenos
CA3107077A1 (en) 2018-08-07 2020-02-13 Glaxosmithkline Biologicals Sa Processes and vaccines
US20210220462A1 (en) 2018-08-23 2021-07-22 Glaxosmithkline Biologicals Sa Immunogenic proteins and compositions
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
CN113166733B (zh) 2018-11-16 2024-12-31 港大科桥有限公司 活减毒流感b病毒组合物及其制备和使用方法
WO2020115171A1 (en) 2018-12-06 2020-06-11 Glaxosmithkline Biologicals Sa Immunogenic compositions
WO2020121159A1 (en) 2018-12-12 2020-06-18 Pfizer Inc. Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
WO2020128012A1 (en) 2018-12-21 2020-06-25 Glaxosmithkline Biologicals Sa Methods of inducing an immune response
JP7239509B6 (ja) 2019-02-22 2023-03-28 ファイザー・インク 細菌多糖類を精製するための方法
CN113573730A (zh) 2019-03-05 2021-10-29 葛兰素史密斯克莱生物公司 乙型肝炎免疫方案和组合物
CA3136278A1 (en) 2019-04-10 2020-10-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
US20220221455A1 (en) 2019-04-18 2022-07-14 Glaxosmithkline Biologicals Sa Antigen binding proteins and assays
EP3770269A1 (en) 2019-07-23 2021-01-27 GlaxoSmithKline Biologicals S.A. Quantification of bioconjugate glycosylation
EP4004018A1 (en) 2019-07-24 2022-06-01 GlaxoSmithKline Biologicals SA Modified human cytomegalovirus proteins
EP4010014A1 (en) 2019-08-05 2022-06-15 GlaxoSmithKline Biologicals S.A. Immunogenic composition
MX2022001489A (es) 2019-08-05 2022-03-02 Glaxosmithkline Biologicals Sa Proceso para la preparacion de una composicion que comprende un polipeptido de proteina d.
EP3777884A1 (en) 2019-08-15 2021-02-17 GlaxoSmithKline Biologicals S.A. Immunogenic composition
EP4028051A1 (en) 2019-09-09 2022-07-20 GlaxoSmithKline Biologicals S.A. Immunotherapeutic compositions
MX2022005252A (es) 2019-11-01 2022-06-08 Pfizer Composiciones de escherichia coli y metodos de las mismas.
US20230045642A1 (en) 2019-12-19 2023-02-09 Glaxosmithkline Biologicals Sa S. aureus antigens and compositions thereof
NL2027383B1 (en) 2020-01-24 2022-04-06 Aim Immunotech Inc Methods, compositions, and vaccines for treating a virus infection
EP4103587A1 (en) 2020-02-14 2022-12-21 Immunor AS Corona virus vaccine
US20230085173A1 (en) 2020-02-21 2023-03-16 Pfizer Inc. Purification of saccharides
PE20230170A1 (es) 2020-02-23 2023-02-01 Pfizer Composiciones de escherichia coli y sus metodos
US20230277657A1 (en) 2020-05-05 2023-09-07 Glaxosmithkline Biologicals Sa Microfluidic mixing device and methods of use
WO2022029024A1 (en) 2020-08-03 2022-02-10 Glaxosmithkline Biologicals Sa Truncated fusobacterium nucleatum fusobacterium adhesin a (fada) protein and immunogenic compositios thereof
IL302362A (en) 2020-10-27 2023-06-01 Pfizer ESCHERICHIA COLI preparations and their methods
US12138302B2 (en) 2020-10-27 2024-11-12 Pfizer Inc. Escherichia coli compositions and methods thereof
CA3200602A1 (en) 2020-11-04 2022-05-12 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
CA3200968A1 (en) 2020-11-10 2022-05-19 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
KR20230110545A (ko) 2020-11-19 2023-07-24 칼리버 임뮤노쎄라퓨틱스, 인크. 종양 미세환경 재형성에 의한 종양용해 면역요법
AU2021392894B2 (en) 2020-12-02 2024-09-19 Glaxosmithkline Biologicals Sa Donor strand complemented fimh
US12357681B2 (en) 2020-12-23 2025-07-15 Pfizer Inc. E. coli FimH mutants and uses thereof
WO2022147373A1 (en) 2020-12-31 2022-07-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibody-guided pcsk9-mimicking immunogens lacking 9-residue sequence overlap with human proteins
US20220226465A1 (en) 2021-01-18 2022-07-21 ConserV Bioscience Coronavirus Immunogenic Compositions, Methods and Uses Thereof
JP2024506364A (ja) 2021-02-11 2024-02-13 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Ｈｐｖワクチンの製造
WO2022178196A1 (en) 2021-02-19 2022-08-25 Sanofi Pasteur Inc. Meningococcal b recombinant vaccine
EP4294433A1 (en) 2021-02-22 2023-12-27 GlaxoSmithKline Biologicals SA Immunogenic composition, use and methods
MX2023012608A (es) 2021-04-30 2023-11-03 Kalivir Immunotherapeutics Inc Virus oncoliticos para la expresion modificada del mhc.
EP4346893A2 (en) 2021-05-28 2024-04-10 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
PE20240090A1 (es) 2021-05-28 2024-01-16 Pfizer Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados y sus usos
WO2023020992A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Novel methods
WO2023020994A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Novel methods
WO2023020993A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Novel methods
EP4433080A1 (en) 2021-11-18 2024-09-25 Matrivax, Inc. Immunogenic fusion protein compositions and methods of use thereof
CA3247998A1 (en) 2022-01-13 2023-07-20 Pfizer Inc. Immunogenic compositions based on conjugated capsular saccharidic antigens and their uses
US20250101067A1 (en) 2022-01-28 2025-03-27 Glaxosmithkline Biologicals Sa Modified human cytomegalovirus proteins
US20250163484A1 (en) 2022-02-25 2025-05-22 Pfizer Inc. Methods for Incorporating Azido Groups in Bacterial Capsular Polysaccharides
AU2023268745A1 (en) 2022-05-11 2024-11-07 Pfizer Inc. Process for producing of vaccine formulations with preservatives
GB202215634D0 (en) 2022-10-21 2022-12-07 Glaxosmithkline Biologicals Sa Polypeptide scaffold
WO2024110827A1 (en) 2022-11-21 2024-05-30 Pfizer Inc. Methods for preparing conjugated capsular saccharide antigens and uses thereof
KR20250107930A (ko) 2022-11-22 2025-07-14 화이자 인코포레이티드 접합된 피막 사카라이드 항원을 포함하는 면역원성 조성물 및 그의 용도
CN120513083A (zh) 2022-12-01 2025-08-19 辉瑞大药厂 肺炎链球菌缀合物疫苗制剂
EP4637812A1 (en) 2022-12-19 2025-10-29 GlaxoSmithKline Biologicals S.A. Hepatitis b compositions
EP4658302A1 (en) 2023-02-02 2025-12-10 GlaxoSmithKline Biologicals S.A. Immunogenic composition
EP4661911A1 (en) 2023-02-10 2025-12-17 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024201324A2 (en) 2023-03-30 2024-10-03 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
KR20250169621A (ko) 2023-04-14 2025-12-03 화이자 인코포레이티드 접합된 피막 사카라이드 항원을 포함하는 면역원성 조성물 및 그의 용도
WO2024224266A1 (en) 2023-04-24 2024-10-31 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024241172A2 (en) 2023-05-19 2024-11-28 Glaxosmithkline Biologicals Sa Methods for eliciting an immune response to respiratory syncycial virus and streptococcus pneumoniae infection
WO2025133971A1 (en) 2023-12-23 2025-06-26 Pfizer Inc. Improved methods for producing bacterial capsular saccharide glycoconjugates
WO2025186705A2 (en) 2024-03-06 2025-09-12 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2025191415A1 (en) 2024-03-11 2025-09-18 Pfizer Inc. Immunogenic compositions comprising conjugated escherichia coli saccharides and uses thereof
WO2025219904A1 (en) 2024-04-19 2025-10-23 Pfizer Inc. Improved methods for producing glycoconjugates by reductive amination in aprotic solvent

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US703355A (en) * 1901-11-05 1902-06-24 Bertt H Brockway Current-motor.
US4196192A (en) * 1977-10-28 1980-04-01 American Cyanamid Company Combined Haemophilus influenzae type b and pertussis vaccine
US4620978A (en) * 1982-04-07 1986-11-04 The United States Of America As Represented By The Department Of Health And Human Services Hepatitis A virus purified and triply cloned
GB8508685D0 (en) * 1985-04-03 1985-05-09 Minor P D Peptides
US4877611A (en) * 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US4806352A (en) * 1986-04-15 1989-02-21 Ribi Immunochem Research Inc. Immunological lipid emulsion adjuvant
US5026557A (en) * 1987-09-09 1991-06-25 The Liposome Company, Inc. Adjuvant composition
JPH085804B2 (ja) * 1988-04-28 1996-01-24 財団法人化学及血清療法研究所 Ａ型及びｂ型肝炎混合アジュバントワクチン
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
DE3916595A1 (de) * 1989-05-22 1990-11-29 Boehringer Mannheim Gmbh Verfahren zur nichtradioaktiven messung der nucleinsaeuresynthese in eukaryontischen zellen
SG48175A1 (en) * 1989-07-25 1998-04-17 Smithkline Beecham Biolog Novel antigens and method for their preparation
US5100662A (en) * 1989-08-23 1992-03-31 The Liposome Company, Inc. Steroidal liposomes exhibiting enhanced stability
CH678394A5 (fi) * 1990-08-22 1991-09-13 Cerny Erich H
AU654970B2 (en) * 1990-09-28 1994-12-01 Smithkline Beecham Biologicals (Sa) Derivatives of gp160 and vaccines based on gp160 or a derivative thereof, containing an adjuvant
GB9106048D0 (en) * 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccines
JPH06503821A (ja) * 1990-12-20 1994-04-28 スミスクライン・ビーチャム・バイオロジカルス（ソシエテ・アノニム） Ｂ型肝炎表面抗原に基づくワクチン
GB9028038D0 (en) * 1990-12-24 1991-02-13 Nycomed Pharma As Test method and reagent kit therefor
GB9105992D0 (en) * 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
MA22842A1 (fr) * 1992-03-27 1993-10-01 Smithkline Beecham Biolog Procede de preparation de compositions de vaccin.
AU6141094A (en) * 1993-02-19 1994-09-14 Smithkline Beecham Biologicals (Sa) Influenza vaccine compositions containing 3-o-deacylated monophosphoryl lipid a

Also Published As

Publication number Publication date
ES2162139T5 (es) 2008-05-16
IL109056A0 (en) 1994-06-24
WO1994021292A1 (en) 1994-09-29
FI954514A0 (fi) 1995-09-22
FI110844B (fi) 2003-04-15
JPH08508722A (ja) 1996-09-17
NO953759L (no) 1995-09-22
DE69428136D1 (de) 2001-10-04
ES2162139T3 (es) 2001-12-16
EP1175912A1 (en) 2002-01-30
DK0689454T3 (da) 1997-12-08
HU9501979D0 (en) 1995-08-28
PL178578B1 (pl) 2000-05-31
JP2005015487A (ja) 2005-01-20
ATE204762T1 (de) 2001-09-15
DK0689454T4 (da) 2005-05-30
US5776468A (en) 1998-07-07
NO322578B1 (no) 2006-10-30
CZ289476B6 (cs) 2002-01-16
HK1045935A1 (en) 2002-12-20
CZ246795A3 (en) 1996-03-13
AP9400629A0 (en) 1994-04-30
PL310598A1 (en) 1995-12-27
IL109056A (en) 1998-06-15
ATE157882T1 (de) 1997-09-15
DE69405551D1 (de) 1997-10-16
NO20054701L (no) 1995-09-22
JP4837906B2 (ja) 2011-12-14
GR3025483T3 (en) 1998-02-27
NO20054701D0 (no) 2005-10-12
HU219056B (hu) 2001-02-28
AU685443B2 (en) 1998-01-22
MA23143A1 (fr) 1994-10-01
DK0812593T4 (da) 2008-05-13
EP0689454B1 (en) 1997-09-10
EP0689454A1 (en) 1996-01-03
NO953759D0 (no) 1995-09-22
JP4028593B2 (ja) 2007-12-26
DE69405551T3 (de) 2005-10-20
DE69405551T2 (de) 1998-03-26
PT812593E (pt) 2002-01-30
DE69428136T2 (de) 2002-05-02
SG48309A1 (en) 1998-04-17
SK117395A3 (en) 1996-11-06
AU6426494A (en) 1994-10-11
DE69428136T3 (de) 2008-07-10
CN1119829A (zh) 1996-04-03
AP515A (en) 1996-08-09
HK1023499A1 (en) 2000-09-15
SA94140762B1 (ar) 2005-05-31
ES2109685T3 (es) 1998-01-16
DZ1763A1 (fr) 2002-02-17
HK1011930A1 (en) 1999-07-23
EP0812593A1 (en) 1997-12-17
EP0812593B2 (en) 2008-01-02
EP0689454B2 (en) 2005-02-23
HUT72916A (en) 1996-06-28
NZ263538A (en) 1996-10-28
CN1087176C (zh) 2002-07-10
BR9405957A (pt) 1995-12-12
KR100310510B1 (ko) 2002-07-04
ES2109685T5 (es) 2005-09-01
EP0812593B1 (en) 2001-08-29
EP0812593B8 (en) 2010-11-10
DK0812593T3 (da) 2001-11-12

Similar Documents

Publication Publication Date Title
FI954514L (fi) 3-O-deasyloitua monofosforyylilipidiä A sisältävä rokotekoostumus
FI944442A0 (fi) 3-O-deasyloitua monofosforyylilipidiä A sisältäviä maksatulehdusrokotteita
DE69313134D1 (de) Adjuvantien enthaltende impfstoffzusammensetzung
KR900011476A (ko) 백신 제제
AP9400621A0 (en) Influenza vaccine compositions
DE69027112D1 (de) Impfstoffzusammensetzung
FI944052A7 (fi) Oraalinen rokote
FI925032A7 (fi) Rokotekoostumukset
ATE134386T1 (de) Vakzin-zusammensetzung
NO943251D0 (no) Oral vaksine
IL94510A0 (en) Influenza vaccine
BR7200790U (pt) Original embalagem expositora instrutiva
NO923242D0 (no) Oral vaksine
IE900354L (en) Vaccine composition

Legal Events

Date Code Title Description
MA Patent expired